arrow
H

Hsien-Li Kao

National Taiwan University Hospital
H指数:39
被引数:5,725

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial

对糖尿病非血流限制性易损性动脉粥样硬化冠状动脉斑块的预防性经皮冠状动脉介入治疗:PREVENT试验

2025-05-290
PRE
Impact of Optical Coherence Tomography-Based Post-PCI Physiology Assessment to Predict Clinical Outcomes

光学相干断层扫描引导的PCI术后生理学评估对预测临床结局的影响

2025-05-220
OA
Validation of the Zwolle Risk Score in STEMI Patients Undergoing Primary PCI: Insights from the ISCAS-STEMI COVID-19 Registry

Zwolle风险评分在行急诊PCI的STEMI患者中的验证:来自ISCA-STEMI COVID-19登记研究的数据

2025-04-160
PRE
Gut microbes with the gbu genes determine TMAO production from L-carnitine intake and serve as a biomarker for precision nutrition

具有gbu基因的肠道微生物决定了左旋肉碱摄入的TMAO产量,并作为精确营养的生物标志物

2024-12-260
OAAI
Impact of hypertension on mortality in patients with ST-elevation myocardial infarction undergoing primary angioplasty: insights from the international multicenter ISACS-STEMI registry
2024-10-110
PRE
A risk stratification model modified from the U.S. guideline could be applied in an Asian population with or without ASCVD: Validation study
2024-06-010
OAAI
Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT) :a multicentre, open-label, randomised controlled trial
LANCET
IF88.5
2024-05-0147
PRE
Low- or standard-dose edoxaban versus antiplatelet therapy for leaflet thrombus and cerebral thromboembolism after TAVR: A prespecified analysis of randomized ADAPT-TAVR trial
2024-03-011
PRE
Impact of the COVID-19 Pandemic on Global TAVR Activity The COVID-TAVI Study

新型冠状病毒肺炎大流行对全球TAVR活动的影响covid-tavi研究

2024-02-013
OAAI
Frequency, Predictors, and Clinical Impact of Valvular and Perivalvular Thrombus After Transcatheter Aortic Valve Replacement
2023-12-016
PRE